Journal
BLOOD
Volume 119, Issue 4, Pages 1018-1028Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2011-06-363887
Keywords
-
Categories
Funding
- National Institutes of Health
- Multiple Myeloma Research and International Waldenstrom's Macroglobulinemia Foundations [R01CA151354]
- National Cancer Institute (NCI)
Ask authors/readers for more resources
Tumor progression usually proceeds through several sequential stages, any of which could be targets for interrupting the progression process if one understood these steps at the molecular level. We extracted nascent plasma cell tumor (PCT) cells from within inflammatory oil granulomas (OG) isolated from IP pristane-injected BALB/c.iMyc(E mu) mice at 5 different time points during tumor progression. We used laser capture microdissection to collect incipient PCT cells and analyzed their global gene expression on Affymetrix Mouse Genome 430A microarrays. Two independent studies were performed with different sets of mice. Analysis of the expression data used ANOVA and Bayesian estimation of temporal regulation. Genetic pathway analysis was performed using Meta Core (Gene Go) and IPA (Ingenuity). The gene expression profiles of PCT samples and those of undissected OG samples from adjacent sections showed that different genes and pathways were mobilized in the tumor cells during tumor progression, corn-pared with their stroma. Our analysis implicated several genetic pathways in PCT progression, including biphasic (up-and then down-regulation) of the Spp1/osteopontin-dependent network and up-regulation of mRNA translation/protein synthesis. The latter led to a biologic validation study that showed that the AMPK-activating diabetes drug, metformin, was a potent specific PCT inhibitor in vitro. (Blood. 2012;119(4)1018-1028)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available